Changes to Innate Pharma and Sanofi ANKET collaboration

French drug developer Innate Pharma’s (Euronext Paris: IPH) shares were up 5.6% at 1.81 euros in early trading after it announced a review of its January 2016 research collaboration and license agreement with Sanofi (Euronext: SAN).

As previously disclosed and in alignment with its current strategic priorities, Sanofi will opt to pursue the development of SAR’514/IPH6401 (BCMA ANKET) in autoimmune indications under the terms of the 2016 license agreement;

In alignment with both company's current strategic priorities, Sanofi and Innate agreed to terminate the 2016 Agreement as it relates to SAR’579/IPH6101 (CD123 ANKET). As a result Innate will regain its rights on SAR’579/IPH6101 (CD123 ANKET).